InvestSMART

Amplia Therapeutics Limited (ASX: ATX) - Announcements

Current share price for ATX : $0.110 0.005 (4.35%)+

ASX company news and announcements for Amplia Therapeutics Limited (ATX) are delayed by 20 minutes from the time of their release between 7.30am and 7.30pm EDT and are in PDF format. All Amplia Therapeutics Limited (ATX) ASX announcements deemed to be price sensitive will be highlighted with . If you are looking for ASX announcements for companies other than Amplia Therapeutics Limited (ATX), please use our Company Announcements tool to search across all ASX-listed companies.

Latest company announcements for Amplia Therapeutics Limited (ATX)

Search all Announcements
Market Cap ($m) Headline Release
date/time+		 Price at
release+		 Current
price+		 Gain/Loss View
$56 Amplia and ANZGOG announce Ovarian Cancer Study 8 May 2026 8:29AM $0.135 $0.110 fallen by 18.52%
$56 Quarterly Activities/Appendix 4C Cash Flow Report 28 Apr 2026 9:38AM $0.165 $0.110 fallen by 33.33%
$56 ACCENT Trial Mature Data Presented at AACR Conference 22 Apr 2026 8:26AM $0.155 $0.110 fallen by 29.03%
$56 Amplia MD Responds to Questions Regarding AMPLICITY Trial 8 Apr 2026 2:06PM $0.155 $0.110 fallen by 29.03%
$56 Amplia Therapeutics Halts Recruitment in AMPLICITY Trial 7 Apr 2026 8:40AM $0.240 $0.110 fallen by 54.17%
$56 Amplia Reports Improved Responses & Survival in ACCENT trial 23 Mar 2026 9:35AM $0.113 $0.110 fallen by 2.22%
$56 Trading Halt 19 Mar 2026 10:57AM $0.113 $0.110 fallen by 2.22%
$56 Pause in Trading 19 Mar 2026 9:52AM $0.113 $0.110 fallen by 2.22%
$56 Benefit of Narmafotinib in kRas-Mutated Cancer Models 9 Mar 2026 8:14AM $0.110 $0.110 fallen by 0%
$56 Appointment of Chief Financial Officer 25 Feb 2026 8:10AM $0.130 $0.110 fallen by 15.38%
$56 Amplia Emergence 2026 Conference Presentation 18 Feb 2026 8:11AM $0.120 $0.110 fallen by 8.33%
$56 US Sites For AMPLICITY Pancreatic Cancer Trial Open 11 Feb 2026 9:09AM $0.120 $0.110 fallen by 8.33%
$56 Quarterly Activities/Appendix 4C Cash Flow Report 30 Jan 2026 8:28AM $0.130 $0.110 fallen by 15.38%
$56 Change in substantial holding 22 Jan 2026 4:44PM $0.140 $0.110 fallen by 21.43%
$56 Narmafotinib Large-Scale Manufacture Complete 22 Jan 2026 8:21AM $0.135 $0.110 fallen by 18.52%
$56 ACCENT Data Presented at 2026 ASCO GI Cancer Symposium 9 Jan 2026 4:20PM $0.175 $0.110 fallen by 37.14%
$56 Amplia Enters 2nd Agreement with Drug Screening Co Next Bio 19 Dec 2025 8:26AM $0.120 $0.110 fallen by 8.33%
$56 Additional Confirmed Response Reported-Investor Presentation 11 Dec 2025 7:56PM $0.128 $0.110 fallen by 13.73%
$56 Key narmafotinib Patent Granted in the US 3 Dec 2025 8:30AM $0.120 $0.110 fallen by 8.33%
$56 Half Yearly Report and Accounts 27 Nov 2025 4:44PM $0.140 $0.110 fallen by 21.43%
$56 Positive Response from US FDA to Amplia's Type D Meeting 20 Nov 2025 9:59AM $0.115 $0.110 fallen by 4.35%
$56 Notification regarding unquoted securities - ATX 10 Nov 2025 4:42PM $0.130 $0.110 fallen by 15.38%
$56 Amplia Commences Trading on U.S. OTCQB Venture Market 31 Oct 2025 8:19AM $0.135 $0.110 fallen by 18.52%
$56 Quarterly Activities/Appendix 4C Cash Flow Report 29 Oct 2025 9:03AM $0.125 $0.110 fallen by 12%
$56 Amplia Receives R&D Tax Rebate Totalling $3.77 Million 28 Oct 2025 9:13AM $0.130 $0.110 fallen by 15.38%

26 - 50 of 543 results

Page 2 of 22

  • + Company announcements and prices are delayed by least 20 minutes. Prices are indicative only.

DISCLOSURE: InvestSMART Group Limited employees may have an interest in the securities and managed funds displayed via this service. Please refer to our Financial Services Guide for more information.

Data shown on this website is sourced by Morningstar
© Morningstar. All rights reserved. Neither any Morningstar company nor any of their content providers guarantee the data or content contained herein to be accurate, complete or timely nor will they have any liability for its use or distribution. Any general advice has been prepared by Morningstar Australasia Pty Ltd (ABN: 95 090 665 544, AFSL: 240892) and/or Morningstar Research Limited, subsidiaries of Morningstar, Inc, without reference to your objectives, financial situation or needs. You should consider the advice in light of these matters and, if applicable, the relevant Product Disclosure Statement (in respect of Australian products) or Investment Statement (in respect of New Zealand products) before making any decision to invest. No Morningstar-affiliated company or any of their employees is providing you with personalised financial advice. To obtain advice tailored to your particular circumstances, please contact a professional financial adviser. Some material is copyright and published under licence from ASX Operations Pty Limited ACN 004 523 782 ("ASXO"). Data and content is provided for personal use only.